Literature DB >> 31759982

Evaluating the role of hsa-miR-200c in reversing the epithelial to mesenchymal transition in prostate cancer.

Sanmitra Basu1, Amrita Chaudhary2, Pramita Chowdhury1, Deepmala Karmakar1, Keya Basu3, Dilip Karmakar4, Jyotirmoy Chatterjee2, Sanghamitra Sengupta5.   

Abstract

Deregulated epithelial-to-mesenchymal transition constitutes one of the major aspects of cancer progression. In this study, to identify key molecular principles of EMT pathway in prostate carcinogenesis, an elaborate gene expression profiling was conducted by qRT-PCR and Western blot analyses. A preponderance of mesenchymal trait was observed in the pathological samples of prostate cancer. To simulate an appropriate in vitro model, PC3 cell line was subjected to hypoxic stress, which resulted in elevated expression of vimentin along with EMT-mediating transcription factors Zeb1 and Slug. To conciliate this mesenchymal behavior of PC3 cells, hsa-miR-200c was deliberately overexpressed which led to a marked reduction of cell motility and expression of vimentin, N-cadherin, Zeb1 and Slug with concurrent increase in level of β-catenin. hsa-miR-200c was demonstrated to appease hypoxia-aggravated changes in cellular morphology by coordinated repression of vimentin, Zeb1 and Slug. Mode of action for hsa-miR-200c was mediated through transcriptional repression of Zeb1 and Slug interacting with E-box sequences in the vimentin promoter as documented by promoter assay. This ability of hsa-miR-200c to reclaim epithelial traits leads to the anticipation that molecular reprogramming of Zeb1-Slug/vimentin axis may relieve aggressiveness of prostate cancer.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Epithelial-to-mesenchymal transition; Prostate cancer; Slug; Vimentin; Zeb1; hsa-miR-200c

Mesh:

Substances:

Year:  2019        PMID: 31759982     DOI: 10.1016/j.gene.2019.144264

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  8 in total

Review 1.  MicroRNA mediated therapeutic effects of natural agents in prostate cancer.

Authors:  Km Anjaly; A B Tiku
Journal:  Mol Biol Rep       Date:  2021-07-24       Impact factor: 2.316

Review 2.  MicroRNAs and Their Influence on the ZEB Family: Mechanistic Aspects and Therapeutic Applications in Cancer Therapy.

Authors:  Milad Ashrafizadeh; Hui Li Ang; Ebrahim Rahmani Moghadam; Shima Mohammadi; Vahideh Zarrin; Kiavash Hushmandi; Saeed Samarghandian; Ali Zarrabi; Masoud Najafi; Reza Mohammadinejad; Alan Prem Kumar
Journal:  Biomolecules       Date:  2020-07-12

Review 3.  The Impact of Non-coding RNAs in the Epithelial to Mesenchymal Transition.

Authors:  Bashdar Mahmud Hussen; Hamed Shoorei; Mahdi Mohaqiq; Marcel E Dinger; Hazha Jamal Hidayat; Mohammad Taheri; Soudeh Ghafouri-Fard
Journal:  Front Mol Biosci       Date:  2021-03-26

4.  Role of IGF2 in the Study of Development and Evolution of Prostate Cancer.

Authors:  P Porras-Quesada; J M González-Cabezuelo; V Sánchez-Conde; I Puche-Sanz; V Arenas-Rodríguez; C García-López; J F Flores-Martín; J M Molina-Hernández; M J Álvarez-Cubero; L J Martínez-González; F Vázquez-Alonso
Journal:  Front Genet       Date:  2022-01-04       Impact factor: 4.599

5.  Construction of Potential Gene Expression and Regulation Networks in Prostate Cancer Using Bioinformatics Tools.

Authors:  Heyu Liu; Lirong Li; Yuan Fan; Yaping Lu; Changhong Zhu; Wei Xia
Journal:  Oxid Med Cell Longev       Date:  2021-08-31       Impact factor: 6.543

6.  Quaking I-5 protein inhibits invasion and migration of kidney renal clear cell carcinoma via inhibiting epithelial-mesenchymal transition suppression through the regulation of microRNA 200c.

Authors:  Ruili Zhang; Wenguang Wang; Ainiwaer Aimudula; Songmei Lu; Pengfei Lu; Remila Aihaiti; Yongxing Bao
Journal:  Transl Androl Urol       Date:  2021-10

7.  MiR-373 Inhibits the Epithelial-Mesenchymal Transition of Prostatic Cancer via Targeting Runt-Related Transcription Factor 2.

Authors:  Jianyi Pang; Limei Dai; Chen Zhang; Qinglei Zhang
Journal:  J Healthc Eng       Date:  2021-06-29       Impact factor: 2.682

Review 8.  Non-Coding RNAs Set a New Phenotypic Frontier in Prostate Cancer Metastasis and Resistance.

Authors:  Joshua Altschuler; Jennifer A Stockert; Natasha Kyprianou
Journal:  Int J Mol Sci       Date:  2021-02-20       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.